Do ACE inhibitors offer specific benefits in the antihypertensive treatment of diabetic patients?: 17 years of unfulfilled promises

Diabetologia

Volumn 41, Issue 5, 1998, Pages 598-602

  Sawicki, P T ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIUM DERIVED RELAXING FACTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HYDRALAZINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; METOPROLOL; NIFEDIPINE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; ENDOTHELIUM LESION; HUMAN; HYPERTENSION; META ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; TIME FACTORS;

EID: 0031979276     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050953     Document Type: Review

References (53)

1. Cushman DW, Ondetti MA (1991) History of the design of captopril and related inhibitors of angiotensin-converting enzyme. Hypertension 17: 589-592
2. Joint National Committee (1988) The 1988 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 148: 1023-1038
3. Joint National Committee (1993) The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 153: 154-183
4. American Diabetes Association (1997) Diabetic nephropathy. Diabetes Care 20 [Suppl I]: S24-S27
5. Kaplan NM, Rosenstock J, Raskin P (1987) A differing view of treatment of hypertension in patients with diabetes mellitus. Arch Intern Med 147: 1160-1162
6. Anonymous, Consensus statement (1993) Treatment of hypertension in diabetes. Diabetes Care 10: 1394-1401
7. The Hypertension Detection and Follow-up Programme Co-operative Research Group (1985) Mortality findings for stepped-care and referred care participants in the Hypertension Detection and Follow-up Programme, stratified by other risk factors. Prev Med 14: 312-335
8. Curb JD, Pressel SL, Cutler JA et al. for the Systolic Hypertension in the Elderly Program Co-operative Research Group (1996) Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276: 1886-1892
9. Collins R, Peto R (1994) Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD (ed) Textbook of hypertension. Blackwell. Oxford, pp 1156-1164
10. World Health Organisation (1996) Hypertension Control. Report of a WHO expert committee. World Health Organisation, Geneva
11. Feener EP, King GL (1997) Vascular dysfunction in diabetes mellitus. Lancet 350: [Suppl I]: 9-13
12. Baron AD, Steinberg HO (1997) Endothelial function, insulin sensitivity, and hypertension. Circulation 96: 725-726
13. Polderman KH, Stehouwer CDA, van Kamp GJ, Gooren LJG (1996) Effects of insulin on endothelium-derived vasoactive substances. Diabetologia 39: 1284-1292
14. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD (1994) Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent - a novel action of insulin to increase nitric oxide release. J Clin Invest: 94: 1172-1179
15. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N (1997) Basal nitric oxide synthesis in essential hypertension. Lancet 349: 837-842
16. Laakso M, Edelman SV, Brechtel G, Baron AD (1992) Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41: 1076-1083
17. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA (1996) Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27: 567-574
18. Lüscher TF, Raij L, Vanhoutte PM (1987) Endothelium-dependent responses in normotensive and hypertensive Dahl rats. Hypertension 9: 157-163
19. Panza JA, Ouyyumi AA, Brusch JE Jr, Epstein SE (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323: 22-27
20. Rizebos J, Vleeming W, Booms RB et al. (1994) Comparison of the antiatherogonic effects of isradipine and ramipril in cholostorol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction. J Cardiovasc Pharmacol 23: 415-423
21. Clozel M, Kuhn H, Hefti F (1990) Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension 16: 532-540
22. Hirooka Y, Imaizumi T, Masaki H et al. (1992) Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 20: 175-180
23. Mancini J, Henry GC, Macaya C et al. (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94: 258-265
24. Papageorgiou A, Karayiannis A, Athyros V, Douma S, Petidis K, Zamboulis C (1994) Comparative study of the efficacy and safety of quinapril versus lisinopril in patients with mild to moderate essential hypertension. Drug Invest 7: 13-17
25. Osterziehl KJ, Rohring N, Dietz R, Manthey J, Hecht J, Kuber W (1988) Influence of captopril on the arterial baroreceptor reflex in patients with heart failure. Eur Heart J 9: 1137-1145
26. Bijlstra PJ, Smits P, Lutterman JA, Thien TH (1995) Effect of long term angiotensin-converting enzyme inhibition on endothelial function in patients with insulin-resistance syndrome. J Cardiovasc Pharmacol 25: 658-664
27. Smulders RA, Lambert J, Aarsen M, Donker AJM, Stehouwer CDA (1995) The effect of ACE-inhibition on endothelial function in uncomplicated insulin dependent diabetic subjects. Diabetologia 38 [Suppl 1]: A49 (Abstract)
28. Malik RA, Williamson S, Abbott C, Boulton AJM (1997) ACE inhibition fails to improve reduced oxygen tension and the impaired hyperaemic response in diabetic patients: a placebo-controlled clinical trial. Diabet Med 14: S30
29. Warram JH, Laftel LMB, Vasania P, Christlieb AR, Królewski AS (1991) Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 151: 1350-1356
30. Moser M, Blaufox MD, Freis E et al. (1991) Who really determines your patients' prescriptions? JAMA 265: 498-500
31. Sawicki PT, Mühlhauser I, Baba T, Berger M (1990) Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia 33: 121-124
32. Hypertension in Diabetes Study Group (1996) Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control. Diabetologia 39: 1554-1561
33. Harper R, Ennis CN, Heaney AP et al. (1995) A comparison of the effects of low and conventional-dose thiazide diuretics on insulin action in hypertensive patients with NIDDM. Diabetologia 38: 853-859
34. Lacourcière Y, Nadeau A, Poirier L. Tancède G (1993) Captopril or conventional therapy in hypertensive type 2 diabetics. Three-year analysis. Hypertension 21: 786-794
35. Borhani NO, Mercuri M, Borhani PA et al. (1996) Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomised controlled trial. JAMA 276: 785-791
36. Byington RP. Craven TE, Furberg CD, Pahor M (1997) Isradipine, raised glycosylated haemoglobin, and risk for cardiovascular events. Lancet 350: 1075-1076
37. Weidmann P, Buehlen M, de Courten M (1993) Effects of different antihypertensive drugs on human proteinuria. Nephrol Dial Transplant 8: 582-584
38. Parving HH, Rossing P (1994) The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Current Opinion in Nephrology and Hypertension 3: 292-300
39. The EUCLID study group (1997) Randomised placebocontrolled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 1787-1792
40. Morelli E, Loon N, Meyer T, Peters W, Myers BD (1990) Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 39: 76-82
41. Sawicki PT, Berger M (1994) Measuring progression of diabetic nephropathy. Review. Eur J Clin Invest 24: 651-655
42. Bauer JH, Reams GP, Hewett J et al. (1992) A randomised, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 20: 443-457
43. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH (1997) Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 46: 481-487
44. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M (1992) Renal protective effect of enalapril in diabetic nephropathy. BMJ 304: 339-342
45. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New Engl J Med 329: 1456-1462
46. Elving LD, Wetzels JMF, van Lier HJJ, de Nobel E, Berden JHM (1994) Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 37: 604-609
47. Sawicki PT, for the Diabetes Teaching and Treatement Programmes Working Group (1997) Stabilisation of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens. Nephrol Dial Transplant 12: 1890-1899
48. Sawicki PT, Mühlhauser I, Didjurgeit U, Baumgartner A, Bender R, Berger M (1995) Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 13: 933-938
49. Maschio G, Alberti D, Janin G et al. and the Angiolensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group (1996) The effect of the angiotensin-converting-enzyme inhibitor benazapril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945
50. Hill AB (1963) Medical ethics and controlled trials. BMJ 1: 1043-1049
51. Davis BR, for the ALLHAT Research Group (1996) Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens 9: 342-360
52. Passa P, Chatellier G (1996) The DIAB-HYCAR Study. Diabelologia 39: 1662-1667
53. Schrier RW, Estacio RO, Jeffes B (1996) Appropriate blood pressure control in NIDDM (ABCD) trial. Diabetologia 39: 1662-1667